Table 4.
Comparison of overall survival between patients with chemotherapy and no-chemotherapy in specific tumor grades, stages, nodal status and progesterone receptor status using a multivariate Cox proportional hazard model
| Variables | Overall Survival | ||
|---|---|---|---|
| Events | Hazard Ratio (95% Confidence Interval) | P a | |
| N0 ( n = 961) | 613 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.790 (0.555–1.125) | 0.192 | |
| N+ ( n = 544) | 373 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.734 (0.566–0.951) | 0.019 | |
| Grade Well/Moderately n = 940) | 579 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.788 (0.581–1.068) | 0.124 | |
| Grade Poorly/undifferentiated n = 524) | 382 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.628 (0.460–0.859) | 0.004 | |
| Stage I n = 561) | 351 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.644 (0.384–1.081) | 0.096 | |
| Stage II n = 673) | 429 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.628 (0.456–0.866) | 0.004 | |
| Stage III n = 283) | 218 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.696 (0.504–0.963) | 0.029 | |
| PR + Stage I n = 424) | 230 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.603 (0.312–1.167) | 0.133 | |
| PR + Stage II n = 523) | 302 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.783 (0.538–1.140) | 0.202 | |
| PR + Stage III n = 192) | 132 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.571 (0.372–0.875) | 0.010 | |
| PR- Stage I n = 40) | 31 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 1.205 (0.304–4.777) | 0.791 | |
| PR- Stage II n = 55) | 40 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.201 (0.051–0.792) | 0.022 | |
| PR- Stage III n = 30) | 25 | ||
| No-chemotherapy | Reference | ||
| Chemotherapy | 0.242 (0.060–0.972) | 0.046 | |
aP value was adjusted by a multivariate Cox proportional hazard regression model and bold type indicates significance
Note: PR: Progesterone Receptor